September 18, 2024 Dataset Open Access

Gündel, Daniel; Teodoro, Rodrigo; c, Friedrich-Alexander Ludwig a.; Heerklotz a., Anne; Toussaint, Magali; Deuther-Conrad, Winnie; Bormans d., Guy; Brust a., Peter; Kopka, Klaus; Moldovan, Rares-Petru; f, Rareş-Petru Moldovan

Citation Style Language JSON Export

{
  "issued": {
    "date-parts": [
      [
        2024, 
        9, 
        18
      ]
    ]
  }, 
  "author": [
    {
      "family": "G\u00fcndel, Daniel"
    }, 
    {
      "family": "Teodoro, Rodrigo"
    }, 
    {
      "family": "c, Friedrich-Alexander Ludwig a."
    }, 
    {
      "family": "Heerklotz a., Anne"
    }, 
    {
      "family": "Toussaint, Magali"
    }, 
    {
      "family": "Deuther-Conrad, Winnie"
    }, 
    {
      "family": "Bormans d., Guy"
    }, 
    {
      "family": "Brust a., Peter"
    }, 
    {
      "family": "Kopka, Klaus"
    }, 
    {
      "family": "Moldovan, Rares-Petru"
    }, 
    {
      "family": "f, Rare\u015f-Petru Moldovan"
    }
  ], 
  "title": "Data publication: Development and Evaluation of Deuterated [18F]JHU94620 Isotopologues for the Non-invasive Assessment of the Cannabinoid type 2 Receptor in Brain", 
  "id": "3149", 
  "publisher": "Rodare", 
  "type": "dataset", 
  "abstract": "<p>What is already known &bull; Increased expression of the CB2R in the brain is linked to certain neuropathological diseases. &bull; First clinical trials for CB2R-directed therapies are conducted. What this study adds &bull; [18F]JHU94620-d8 provides the potential to quantify the CB2R receptor density in the brain by positron-emission-tomography. Clinical significance &bull; Stratification of patients for CB2R-directed therapies and follow up of the treatment response is needed.</p>", 
  "DOI": "10.14278/rodare.3149"
}